Vimarsana
Biggest News Aggregation in the World

Events Reporting System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Events Reporting System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Events Reporting System Today - Breaking & Trending Today

Link Between Skin Cancer and Immunosuppressants Needs Further Research - Vimarsana News

Link Between Skin Cancer and Immunosuppressants Needs Further Research

At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.

Source: ajmc.com
FDA Adverse Events Reporting System Shows Rise in Alopecia Cases, Use of Monoclonal Antibodies - Vimarsana News

FDA Adverse Events Reporting System Shows Rise in Alopecia Cases, Use of Monoclonal Antibodies

These data represent a significant step toward finding a causal connection for drug-induced alopecia, though further controlled studies may be necessary to isolate certain variables.

FDA Adds Warning To Ozempic Label About Ileus, Intestinal Blockage - Vimarsana News

FDA Adds Warning To Ozempic Label About Ileus, Intestinal Blockage

Here are some gut feelings to watch out for when taking Ozempic or other glucagon-like peptide-1 (GLP-1) receptor agonists.

Source: forbes.com
Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs - Vimarsana News

Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs

The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.

Source: forbes.com
FDA Adds Warning To Ozempic Label About Ileus, Intestinal Blockage - Vimarsana News

FDA Adds Warning To Ozempic Label About Ileus, Intestinal Blockage

Here are some gut feelings to watch out for when taking Ozempic or other glucagon-like peptide-1 (GLP-1) receptor agonists.

Source: forbes.com